We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Allergan plc | NYSE:AGN | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 193.02 | 0 | 01:00:00 |
From May 2019 to May 2024
By Stephen Nakrosis
AbbVie Inc. and Allergan PLC said Tuesday they received clearance from the Federal Trade Commission regarding AbbVie's acquisition of Allergan.
As part of the proposed consent, Allergan will divest brazikumab, "an investigational IL-23 inhibitor in development for autoimmune diseases," to AstraZeneca, the companies said. AbbVie will also divest Zenpep, "a treatment for exocrine pancreatic insufficiency due to cystic fibrosis and other conditions," to Nestle, who will also acquire Viokace, another pancreatic enzyme preparation, as part of the deal.
AbbVie and Allergan also amended their agreement so only one Allergan director will join the AbbVie board after the deal closes. Allergan's current Chairman and Chief Executive Brent Saunders "has elected not to join the AbbVie Board to provide more flexibility to pursue other opportunities in the sector," the companies said.
In June, the two companies announced a $63 billion deal that would see AbbVie buy Allergan.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
May 05, 2020 18:38 ET (22:38 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Allergan Chart |
1 Month Allergan Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
